Subscription Service
BioInvent International • SE-223 70 Lund, Sweden • Visiting: Sölvegatan 41, Lund, Sweden • Tel: +46 (0)46-286 85 50 • E-mail: info@bioinvent.com
BioInvent has been listed on the NASDAQ OMX Stockholm since 2001. Our projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by high-profile partners.